Aquestive Therapeutics AQST 深 沪
等待开盘 09-06 09:30:00 美东时间
5.375
+0.315
+6.23%
华盛通- 最 高5.48
- 今 开5.13
- 成交量 412.13万股
- 最 低 5.12
- 昨 收 5.06
- 总市值 6.50亿
- 52周最高 5.80
- 市盈率 静 --
- 换手率 3.41%
- 52周最低 2.12
- 委 比 -57.16%
- 总股本 1.21亿
- 历史最高 20.696
- 量 比 1.71
- 振 幅 7.11%
- 历史最低 0.618
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 财报大超预期！Ciena科技大涨超23%，美鹰服饰涨近40%
两只绩优股大涨！Ciena科技涨超23%，四季度收入指引为13.2亿美元；美鹰服饰涨近40%，每股收益达0.45美元，大超市场预期>>
09-05 19:03
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shares increased by 30.4% to $2.7 during ...
09-04 20:08
Aquestive Therapeutics Awaits FDA Decision on Anaphylm
Aquestive Therapeutics ( ($AQST) ) has provided an announcement. On September 4...
09-04 19:29
FDA Skips Advisory Committee Meeting For Aquestive Therapeutics' Anaphylm; PDUFA Date Set For January 31, 2026
NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approvalWARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc.
09-04 19:04
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
Aquestive Therapeutics announced that the FDA has informed theCompany that an advisory committee meeting is not required for Anaphylm™. ThePDUFA target action date remains January 31, 2026. Anaphylm, a non-invasive,orally delivered epinephrine product, has the potential to be the first FDA-approved treatment for severe allergic reactions, including anaphylaxis. Administered as athin, dissolvable film under the tongue, Anaphylm offers a device-fre...
09-04 11:00
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive Therapeutics announced that its management team will participate in three upcoming investor conferences in September 2025. The events include a fireside chat at the Cantor Healthcare Conference on September 4, investor meetings at the Wells Fargo Healthcare Conference on September 5, and a presentation at the H.C. Wainwright Global Investor Conference on September 9. Webcasts of these events will be available on the company's website. A...
08-26 11:00
Aquestive Secures $75M Funding Tied to FDA Approval of Oral Allergy Rescue Drug Anaphylm
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery
08-14 18:05
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics has secured $75 million in strategic funding from RTW Investments, subject to FDA approval of Anaphylm™, an innovative epinephrine sublingual film for emergency treatment of allergic reactions. The financing aims to strengthen the company's financial position ahead of potential commercialization. Anaphylm, designed to be an orally administered rescue medication, is compact, lightweight, and easy to carry, offering a potenti...
08-14 10:00
Aquestive Therapeutics Affirms FY2025 Sales Guidance of $44.000M-$50.000M vs $45.059M Est
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2025 sales outlook from $44.000 million-$50.000 million to $44.000 million-$50.000 million vs $45.059 million estimate.
08-12 04:02
Aquestive Therapeutics Q2 EPS $(0.14) Beats $(0.17) Estimate, Sales $10.003M Miss $11.320M Estimate
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 18.13 percent. This is a 366.67 percent decrease over losses of $(0.03) per
08-12 04:02
